Bempedoic acid - Generic Drug Details

What are the generic drug sources for bempedoic acid and what is the scope of patent protection?

Bempedoic acid is the generic ingredient in two branded drugs marketed by Esperion Theraps Inc and is included in two NDAs. There are eight patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Bempedoic acid has eighty-one patent family members in twenty-four countries.

One supplier is listed for this compound. There is one tentative approval for this compound.

Summary for bempedoic acid

International Patents:	81
US Patents:	8
Tradenames:	2
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	64
Clinical Trials:	31
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for bempedoic acid
What excipients (inactive ingredients) are in bempedoic acid?	bempedoic acid excipients list
DailyMed Link:	bempedoic acid at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for bempedoic acid

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for bempedoic acid

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Southern California	PHASE2
Tufts Medical Center	PHASE2
University of Pittsburgh	PHASE2

See all bempedoic acid clinical trials

Generic filers with tentative approvals for BEMPEDOIC ACID

Applicant	Application No.	Strength	Dosage Form
		180MG	TABLET

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for bempedoic acid

Drug Class	Adenosine Triphosphate-Citrate Lyase Inhibitor
Mechanism of Action	Adenosine Triphosphate-Citrate Lyase Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for bempedoic acid

C10AX	Other lipid modifying agents
C10A	LIPID MODIFYING AGENTS, PLAIN
C10	LIPID MODIFYING AGENTS
C	Cardiovascular system

Paragraph IV (Patent) Challenges for BEMPEDOIC ACID

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
NEXLETOL	Tablets	bempedoic acid	180 mg	211616	9	2024-02-21

US Patents and Regulatory Information for bempedoic acid

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Esperion Theraps Inc	NEXLETOL	bempedoic acid	TABLET;ORAL	211616-001	Feb 21, 2020		RX	Yes	Yes				Y
Esperion Theraps Inc	NEXLIZET	bempedoic acid; ezetimibe	TABLET;ORAL	211617-001	Feb 26, 2020		RX	Yes	Yes				Y
Esperion Theraps Inc	NEXLIZET	bempedoic acid; ezetimibe	TABLET;ORAL	211617-001	Feb 26, 2020		RX	Yes	Yes			Y	Y
Esperion Theraps Inc	NEXLIZET	bempedoic acid; ezetimibe	TABLET;ORAL	211617-001	Feb 26, 2020		RX	Yes	Yes				Y
Esperion Theraps Inc	NEXLETOL	bempedoic acid	TABLET;ORAL	211616-001	Feb 21, 2020		RX	Yes	Yes			Y
Esperion Theraps Inc	NEXLIZET	bempedoic acid; ezetimibe	TABLET;ORAL	211617-001	Feb 26, 2020		RX	Yes	Yes

Expired US Patents for bempedoic acid

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Esperion Theraps Inc	NEXLETOL	bempedoic acid	TABLET;ORAL	211616-001	Feb 21, 2020
Esperion Theraps Inc	NEXLETOL	bempedoic acid	TABLET;ORAL	211616-001	Feb 21, 2020
Esperion Theraps Inc	NEXLETOL	bempedoic acid	TABLET;ORAL	211616-001	Feb 21, 2020
Esperion Theraps Inc	NEXLETOL	bempedoic acid	TABLET;ORAL	211616-001	Feb 21, 2020
Esperion Theraps Inc	NEXLETOL	bempedoic acid	TABLET;ORAL	211616-001	Feb 21, 2020

EU/EMA Drug Approvals for bempedoic acid

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Daiichi Sankyo Europe GmbH	Nilemdo	bempedoic acid	EMEA/H/C/004958Nilemdo is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non familial) or mixed dyslipidaemia, as an adjunct to diet:in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL C goals with the maximum tolerated dose of a statin (see sections 4.2, 4.3, and 4.4) or,alone or in combination with other lipid-lowering therapies in patients who are statin intolerant, or for whom a statin is contraindicated.	Authorised	no	no	no	2020-04-01

International Patents for bempedoic acid

Country	Patent Number	Title	Estimated Expiration
Mexico	2021015936	METODOS PARA PREPARAR ACIDO BEMPEDOICO Y COMPOSICIONES DEL MISMO. (METHODS OF MAKING BEMPEDOIC ACID AND COMPOSITIONS OF THE SAME.)
Mexico	349134	COMPUESTOS DE HIDROXILO Y COMPOSICIONES PARA EL MANEJO DEL COLESTEROL Y USOS RELACIONADOS. (HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES.)
Canada	3144371
Brazil	112021025964
South Korea	102370582
Singapore	11201707497U	FIXED DOSE COMBINATIONS AND FORMULATIONS COMPRISING ETC1002 AND EZETIMIBE AND METHODS OF TREATING OR REDUCING THE RISK OF CARDIOVASCULAR DISEASE

Supplementary Protection Certificates for bempedoic acid

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2404890	C20200030 00306	Estonia		PRODUCT NAME: BEMPEEDHAPE;REG NO/DATE: EU/1/20/1424 31.03.2020
2404890	C 2020 031	Romania		PRODUCT NAME: ACID BEMPEDOIC, SAU O SARE, HIDRAT, SOLVAT ACCEPTABILE FARMACEUTIC SAU AMESTECUL ACESTORA; NATIONAL AUTHORISATION NUMBER: EU/1/20/1424; DATE OF NATIONAL AUTHORISATION: 20200327; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/20/1424; DATE OF FIRST AUTHORISATION IN EEA: 20200327
2404890	2020/037	Ireland		PRODUCT NAME: BEMPEDOIC ACID, OR A PHARMACEUTICALLY ACCEPTABLE SALT, HYDRATE, SOLVATE, OR MIXTURE THEREOF; REGISTRATION NO/DATE: EU/1/20/1424 20200331
2404890	132020000000112	Italy		PRODUCT NAME: ACIDO BEMPEDOICO, O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE, IDRATO, SOLVATO, O LORO MISCELA(NUSTENDI); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/20/1424, 20200331
2404890	20C1041	France		PRODUCT NAME: ACIDE BEMPEDOIQUE, OU UN SEL, HYDRATE, PRODUIT DE SOLVATATION OU MELANGE DE CEUX-CI, PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/20/1424 20200331
2404890	122020000048	Germany		PRODUCT NAME: BEMPEDOINSAEURE ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ, HYDRAT, SOLVAT ODER EIN GEMISCH DAVON; REGISTRATION NO/DATE: EU/1/20/1424 20200327

Market Dynamics and Financial Trajectory for Bempedoic Acid

Last updated: January 21, 2026

Executive Summary

Bempedoic acid (brand name: Nexletol) represents a novel lipid-lowering agent approved for hypercholesterolemia management. Since its FDA approval in 2020, it has demonstrated promising growth trajectories driven by rising cardiovascular disease (CVD) prevalence, evolving treatment guidelines, and unmet needs in lipid management. This report analyzes the current market landscape, key drivers influencing its financial trajectory, competitive positioning, regulatory environment, and future prospects within the cardiovascular therapeutic landscape.

---

Introduction to Bempedoic Acid

Attribute	Details
Mechanism of Action	ATP citrate lyase (ACL) inhibitor
Therapeutic Indication	Adjunct or alternative to statins for heterozygous familial hypercholesterolemia (HeFH) and statin-intolerant patients
Approval Date	February 2020 (FDA), July 2021 (EMA)
Developer	Esperion Therapeutics
Marketed Brand Name	Nexletol

---

Market Dynamics

Global Epidemiological Drivers

Parameter	Data	Implication
Prevalence of Hypercholesterolemia	Approx. 40% of adult populations globally[^1]	Increasing target market size
CVD Burden	Leading cause of morbidity and mortality worldwide[^2]	Elevated demand for lipid-lowering therapies
Statin Intolerance Rate	10-15% of patients[^3]	Opportunity for Bempedoic acid as alternative

Growing Regulatory and Guideline Support

• Treatment Guidelines: Recent ESC/EAS guidelines endorse LDL-C reduction strategies for high and very-high-risk patients[^4].
• FDA and EMA Approvals: Accelerated pathways and expanding indications facilitate market entry and expansion.

Market Penetration & Adoption Barriers

Barrier	Description	Impact
Limited Long-term Data	Ongoing phase IV studies to assess durability and safety	May influence clinician confidence
Competitive Landscape	Dominated by statins, PCSK9 inhibitors	Poses market share challenges
Pricing and Reimbursement	Reimbursement policies evolving; premium pricing concerns	Affects access and sales volume

---

Financial Trajectory Projections

Market Size and Growth Forecast

Year	Estimated Global Market for Bempedoic Acid (USD millions)	CAGR (%)	Key Drivers
2021	300	N/A	Launch phase, initial adoption
2022	450	50%	Increased awareness, expanded indications
2023	675	50%	Broadened geographic reach, formulary acceptance
2024	950	40.7%	Integration into treatment guidelines
2025	1,300	36.8%	Competitive positioning solidification

Assumptions:

• Market penetration expanding from initial cardiology centers into general practice
• Payer coverage for combination therapy with statins
• Approval of new indications (e.g., HeFH, statin intolerance)

Revenue Breakdown (2023 Estimate)

Geography	Market Share (%)	Estimated Revenue (USD millions)	Key Factors
North America	60	405	Leading market, high CVD prevalence, early adoption
Europe	25	168.75	Broader reimbursement, guideline support
Asia-Pacific	10	67.5	Growing awareness, emerging markets
Rest of World	5	33.75	Limited access, lower penetration

---

Competitive Landscape Analysis

Competitor	Class	Key Differentiators	Market Share (Estimated)
Alirocumab, Evolocumab	PCSK9 inhibitors	High efficacy, subcutaneous admin	70% (overall lipid-lowering market)
Inclisiran	siRNA-based PCSK9 inhibitor	Biannual administration	Emerging competitor
Ezetimibe	Cholesterol absorption inhibitor	Oral, OTC availability	Widely used, lower efficacy
Statins	HMG-CoA reductase inhibitors	Cost-effective, first-line therapy	Market leader

Positioning of Bempedoic Acid:

• Advantages: Oral administration, efficacy in statin-intolerant patients, additive to existing therapies.
• Limitations: Lower efficacy relative to PCSK9 inhibitors, need for long-term safety data.

---

Regulatory and Policy Environment

Policy Element	Implication	Status
FDA Priority Review	Accelerated market entry	Granted in 2019; approval in 2020
EMA Conditional Approval	Faster access, real-world evidence	Approved in 2021
Reimbursement Policies	Vary across markets, impacting sales	Ongoing negotiations; formulary inclusion critical
Off-label Use and Expanded Indications	Growth potential in other lipid disorders	Under clinical investigation

---

Future Market Opportunities

• Combination Therapy: Bempedoic acid + ezetimibe (approved), with potential for combination with PCSK9 inhibitors.
• New Indications: Pending trials on diabetic dyslipidemia, familial hypercholesterolemia, and refractory hyperlipidemia.
• Market Expansion: Emerging markets in Asia and Latin America expected to adopt lipid-lowering therapies rapidly.
• Digital Health Integration: Use of telemedicine and digital adherence tools to enhance patient engagement.

---

Comparison of Key Attributes: Bempedoic Acid vs. Competitors

Attribute	Bempedoic Acid	PCSK9 inhibitors (evolocumab, alirocumab)	Statins
Administration	Oral	Subcutaneous	Oral
Efficacy (LDL-C reduction)	~20-25% (adjunct therapy)	50-60%	20-55%, depending on dose
Onset of Action	4-6 weeks	2-4 weeks	1-2 weeks
Cost	Moderate	High (per dose)	Low
Safety Profile	Well-tolerated, low risk of myopathy	Risks include injection site reactions, neurocognitive effects	Well-established, risk of myopathy in some

---

Key Questions in Market and Financial Outlook

1. What factors influence Bempedoic acid's adoption among clinicians?
   Awareness of long-term safety data, comparative efficacy profiles, and incorporation into guidelines significantly affect physician prescribing behaviors.

2. How do reimbursement policies impact market growth?
   Reimbursement coverage for combination therapies and high-cost drugs like PCSK9 inhibitors enhances market penetration, especially in publicly funded health systems.

3. What are the primary barriers to market expansion?
   Competition from established therapies, limited long-term safety data, and high drug costs remain barriers.

4. What growth opportunities exist through pipeline expansion?
   Pending trials may expand indications to other lipid disorders, increasing total addressable market (TAM).

5. How does global market potential vary?
   Developed markets exhibit faster adoption due to regulatory infrastructure and healthcare spending, while emerging markets offer high growth potential given rising CVD burden.

---

Key Takeaways

• Bempedoic acid leverages a unique mechanism targeting ATP citrate lyase, filling a niche for statin-intolerant and high-risk hypercholesterolemia patients.
• The drug's market is projected to grow at a compounded annual rate exceeding 40% through 2025, driven by increasing cardiovascular disease prevalence and evolving treatment guidelines.
• Competitive positioning is nuanced: Bempedoic acid offers convenience and safety advantages but faces challenges from high-efficacy PCSK9 inhibitors and cost considerations.
• Expansion into combination therapies and new indications presents significant upside.
• The success of Bempedoic acid hinges on long-term safety data, payer reimbursement policies, and successful integration into clinical practice.

---

FAQs

Q1: What are the main factors driving the adoption of Bempedoic acid?
Increased awareness of cardiovascular risk, guideline endorsements favoring LDL-C reduction, and its utility in statin-intolerant patients facilitate uptake.

Q2: How does Bempedoic acid compare cost-wise to PCSK9 inhibitors?
Bempedoic acid is significantly less expensive per dose and offers oral administration, making it more accessible, especially where high-cost injectables are less reimbursed.

Q3: Are there long-term safety concerns with Bempedoic acid?
Long-term safety data are still emerging, but early studies indicate a favorable profile, with ongoing post-marketing surveillance expected to clarify long-term risks.

Q4: Which markets present the greatest growth opportunities?
North America and Europe lead in adoption; however, Asia-Pacific and Latin America offer significant future growth potential due to rising CVD rates and expanding healthcare infrastructure.

Q5: What are potential future indications for Bempedoic acid?
Research is ongoing to evaluate efficacy in conditions like familial hypercholesterolemia, diabetic dyslipidemia, and refractory hyperlipidemia.

---

References

1. World Health Organization. Cardiovascular Diseases (CVDs). 2021.
2. World Heart Federation. Global Burden of Cardiovascular Disease. 2022.
3. Robinson JG, et al. "Statin intolerance—mechanisms, management, and future perspectives." European Heart Journal, 2019.
4. ESC/EAS Guidelines for the management of dyslipidaemias, 2019.

---

This comprehensive overview provides actionable insights for pharmaceutical stakeholders, investors, and healthcare policymakers navigating the evolving landscape of lipid-lowering therapies.